Skip to main content

Buspirone

ADVERTISEMENT
Identification
Molecular formula
C21H31N5O2
CAS number
36505-84-7
IUPAC name
8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
State
State

At room temperature, Buspirone is in a solid state as a crystalline powder, making it stable and easy to handle outside of a controlled environment.

Melting point (Celsius)
192.00
Melting point (Kelvin)
465.20
Boiling point (Celsius)
318.50
Boiling point (Kelvin)
591.60
General information
Molecular weight
385.50g/mol
Molar mass
385.5030g/mol
Density
1.3610g/cm3
Appearence

Buspirone is a white crystalline powder. It is typically colorless and odorless, providing a neutral appearance.

Comment on solubility

Solubility Characteristics of 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (C21H31N5O2)

The solubility of 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione can be quite complex due to its multifaceted structure. Understanding the solubility of this compound necessitates consideration of various factors, including:

  • Polarity: The presence of polar functional groups, such as the methoxy group and the piperazine ring, can enhance solubility in polar solvents like water.
  • Hydrophobic regions: The spirocyclic structure contributes to regions that are hydrophobic, potentially limiting solubility in aqueous environments.
  • Temperature: Increased temperatures often lead to higher solubility for organic compounds, allowing the spiro and phenyl components to interact more favorably with solvents.
  • pH levels: The ionization of the piperazine group may be affected by pH, offering different solubility profiles in acidic vs. basic conditions.

In summary, the solubility of this compound is attributed to a delicate balance between its hydrophilic and hydrophobic characteristics. As a general observation, it may exhibit better solubility in organic solvents while displaying limited solubility in water. Laboratory tests are essential for accurately determining the solubility in specific environments and under varying conditions.

Interesting facts

Interesting Facts about 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione

This compound, known for its unique structure and multifaceted applications, presents a fascinating area of study within medicinal chemistry. The compound features a spirocyclic architecture that allows it to adopt intriguing conformations, making it a candidate for pharmacological exploration.

Key Highlights:

  • Structure: The presence of both piperazine and methoxyphenyl groups contributes significantly to its pharmacological profile.
  • Activity: Compounds of this type often exhibit potential as neuropharmacological agents, notably in modulating neurotransmitter systems.
  • Synthesis: The synthesis of compounds with spirocyclic structures is a vibrant focus, involving various synthetic methodologies that continue to evolve.

In the quest for new therapeutic agents, the exploration of spirocyclic compounds like this one can lead to breakthroughs in treating various neurological disorders. As highlighted in studies, these compounds may show promising action against conditions such as anxiety and depression, leveraging their interaction with serotonin and dopamine receptors.

Research & Development:

  • Pharmacodynamics: Understanding how this compound interacts with biological targets can reveal its mechanism of action.
  • Clinical Trials: Future studies may pave the way for testing its efficacy and safety in human subjects.
  • Structure-Activity Relationship (SAR): Evaluating how variations in structure affect activity is crucial in drug design.

As we continue to investigate compounds like 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione, the potential for new insights into mental health treatments remains significant. The journey from the laboratory bench to clinical application embodies the true essence of pharmaceutical sciences.

Synonyms
Bmy-7378
21102-94-3
8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione
bmy-7378 free base
8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-8-azaspiro[4.5]decane-7,9-dione
CHEMBL13647
08EI0K81OL
8-Azaspiro[4.5]decane-7,9-dione, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-
8-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4.5)decane-7,9-dione
8-Azaspiro(4.5)decane-7,9-dione, 8-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-
8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
8-{2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione
Tocris-1006
GTPL9
Lopac-B-134
UNII-08EI0K81OL
Lopac0_000206
SCHEMBL6017145
CHEBI:92539
DTXSID70943430
AYYCFGDXLUPJAQ-UHFFFAOYSA-N
BCPP000322
HMS3742M05
BDBM50026917
BCP9000439
CCG-204301
SB19517
SDCCGSBI-0050194.P002
8-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4,5)decane-7,9-dione
NCGC00015126-01
NCGC00015126-02
NCGC00015126-03
NCGC00015126-04
NCGC00015126-05
NCGC00015126-06
NCGC00015126-08
NCGC00024935-01
NCGC00024935-02
NCGC00024935-03
L000137
Q4836102
BRD-K31054881-300-01-3
BRD-K31054881-300-03-9
BRD-K31054881-300-04-7
8-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione
1348935-37-4
8-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione(BMY-7378)